信迪利单抗、安罗替尼与培门冬酶夹心放疗一线治疗新诊断I-II期结外NK/T细胞淋巴瘤的II期研究
这项II期试验(NCT03936452)评估信迪利单抗、安罗替尼与培门冬酶夹心放疗一线治疗新诊断I-II期结外NK/T细胞淋巴瘤的疗效与安全性,58例患者入组,6周期后完全缓解率87.8%,2年无进展生存率87.6%、总生存率97.9%,3-4级治疗相关不良事件发生率41.4%,无治疗相关死亡。
要点
- 6周期后完全缓解率87.8%(43/49),总缓解率87.8%(95%CI 75.2-95.4)。
- 中位随访22.5个月,中位无进展生存、总生存、缓解持续时间均未达到。
- 3-4级治疗相关不良事件发生率41.4%(24/58),无治疗相关死亡。
核心结论
- 信迪利单抗、安罗替尼与培门冬酶夹心放疗一线治疗初治早期结外NK/T细胞淋巴瘤显示出有前景的疗效和良好的安全性。
研究设计与样本
- II期试验(NCT03936452),纳入新诊断I-II期结外NK/T细胞淋巴瘤患者58例。
- 方案为信迪利单抗200 mg联合培门冬酶2500 U/m2(第1天)及安罗替尼12 mg每日一次(第1-14天),每21天为一周期,共3周期,随后行调强放疗,再行3周期全身治疗。
- 主要终点为6周期后完全缓解率,次要终点包括无进展生存、总生存、2周期后完全缓解率、6周期后总缓解率、缓解持续时间及安全性。
主要发现
- 2周期后完全缓解率为55.1%(27/49),6周期后完全缓解率为87.8%(43/49)。
- 6周期后总缓解率为87.8%(43/49;95%CI 75.2-95.4)。
- 中位随访22.5个月(95%CI 20.4-24.6),中位无进展生存、总生存及缓解持续时间均未达到。
- 2年无进展生存率为87.6%(95%CI 78.8-97.4),2年总生存率为97.9%(95%CI 94.0-100),2年缓解持续时间为91.1%(95%CI 83.2-99.8)。
- 3-4级治疗相关不良事件发生率为41.4%(24/58),最常见为高血压(15.5%)、高甘油三酯血症(8.6%)、口腔黏膜炎(6.9%)和贫血(5.2%),无治疗相关死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel highly effective and low-toxicity combination therapy for localized extranodal natural-killer/T-cell lymphoma (ENKTL) remains a clinically unmet need. This phase II trial (NCT03936452) investigated the efficacy and safety of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line treatment in patients with newly-diagnosed stage I-II ENKTL. The patients received sintilimab 200 mg plus pegaspargase 2500 U/m2 on day 1 and anlotinib 12 mg once daily on days 1-14 for three 21-day cycles, followed by intensity-modulated radiotherapy and another three cycles of systemic therapy. The primary endpoint was the complete response rate (CRR) after six treatment cycles. The secondary endpoints included progression-free survival (PFS), overall survival (OS), CRR after two cycles, overall response rate (ORR) after six cycles, duration of response (DOR), and safety. Between May 2019 and July 2021, 58 patients were enrolled. The CRR was 55.1% (27/49) after two cycles and 87.8% (43/49) after six cycles. The ORR was 87.8% (43/49; 95% CI, 75.2-95.4) after six cycles. After a median follow-up of 22.5 months (95% CI, 20.4-24.6), the median PFS, OS, and DOR were not reached. The 2-year PFS, OS, and DOR rates were 87.6% (95% CI, 78.8-97.4), 97.9% (95% CI, 94.0-100), and 91.1% (95% CI, 83.2-99.8), respectively. Grade 3-4 treatment-related adverse events occurred in 41.4% (24/58) of patients, with the most common being hypertension (15.5%), hypertriglyceridemia (8.6%), oral mucositis (6.9%), and anemia (5.2%). No treatment-related deaths occurred. First-line sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy demonstrated promising efficacy in treatment-naïve early-stage ENKTL patients with a favorable safety profile.
引用
- Sun P, Li Y, Li C, et al. A phase II study of sintilimab, anlotinib, and pegaspargase sandwiched with radiotherapy as first-line therapy in patients with newly diagnosed, stage I-II extranodal natural-killer/T-cell lymphoma. Am J Hematol. 2023. PMID: 36970971. doi:10.1002/ajh.26922
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。